Programmed genome editing of the omega-1 ribonuclease of the blood fluke,
Schistosoma mansoni

Wannaporn Ittiprasert[1], Victoria H. Mann[1], Shannon E. Karinshak[1], Avril Coghlan[2], Gabriel
Rinaldi[2], Geetha Sankaranarayanan[2], Apisit Chaidee[1,3], Toshihiko Tanno[4], Chutima
Kumkhaek[5], Pannathee Prangtaworn[1,6], Margaret Mentink-Kane[7], Christina J. Cochran[1], Patrick
Driguez[2], Nancy Holroyd[2], Alan Tracey[2], Rutchanee Rodpai[1,3], Bart Everts[8], Cornelis H.
Hokke[8], Karl F. Hoffmann[9], Matthew Berriman[2], Paul J. Brindley[1]

1. Department of Microbiology, Immunology & Tropical Medicine, & Research Center for
Neglected Diseases of Poverty, School of Medicine & Health Sciences, George Washington
University, Washington, D.C. 20037, USA

2. Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton, CB10 1SA, UK

3. Department of Parasitology, Faculty of Medicine, Khon Kaen University, Khon Kaen, 40002,
Thailand

4. Department of Surgery and the Institute of Human Virology, University of Maryland,
Baltimore, MD 21201, USA

5. Cellular and Molecular Therapeutics Laboratory, National Heart, Lungs and Blood Institute,
National Institutes of Health, Bethesda, MD 20814 USA

6. Department of Parasitology, Faculty of Medicine Siriraj Hospital, Mahidol University,
Bangkok, Thailand 10700

7. Schistosomiasis Resource Center, Biomedical Research Institute, Rockville, MD 20850, USA

8. Department of Parasitology, Leiden University Medical Center, Leiden, Netherlands

9. Institute of Biological, Environmental & Rural Sciences (IBERS), Aberystwyth University,
Aberystwyth, SY23 3DA, UK

Running title　**Genome editing of schistosome *omega-1***

Keywords: *Schistosoma mansoni*; genome editing; CRISPR/Cas9; omega1; ribonuclease;
flatworms; Platyhelminthes; functional genomics; lentivirus; homology directed repair; non-
homologous end joining; double stranded break; Th2 phenotype; monocytic macrophage cell;
granuloma; schistosomiasis

[*]Correspondence, Paul Brindley, pbrindley@gwu.edu

Abstract
35
CRISPR/Cas9 based genome editing has not yet been reported in schistosomes. Here, we tested
this approach by targeting omega-1 (ω1) of *Schistosoma mansoni* as a proof of principle. This
secreted ribonuclease is crucial for Th2 priming and granuloma formation, providing informative
immuno-pathological readouts for programmed genome editing. Schistosome eggs were either
exposed to recombinant Cas9 complexed with a synthetic guide RNA (sgRNA) complementary
to exon 6 of ω1 by electroporation or transduced with pseudotyped lentivirus encoding Cas9 and
the sgRNA. Some eggs were also transduced with a single stranded oligodeoxynucleotide donor
transgene that encoded six stop codons, flanked by 50 nt-long 5'- and 3'-microhomology arms
matching the predicted Cas9-catalyzed double stranded break (DSB) within ω1. CRISPResso
analysis of amplicons spanning the DSB revealed ~4.5% of the reads were mutated by insertions,
deletions and/or substitutions, with an efficiency for homology directed repair of 0.19% insertion
of the donor transgene. Transcripts encoding ω1 were reduced >80%, and lysates of ω1-edited
eggs displayed diminished ribonuclease activity indicative that programmed editing mutated the
ω1 gene. Whereas soluble lysates of wild type eggs polarized Th2 cytokine responses including
IL-4 and IL-5 in human macrophage/T cell co-cultures, diminished levels of these cytokines
followed the exposure to those of ω1-mutated schistosome eggs. Following injection of
schistosome eggs into the tail vein of BALB/c mice, the volume of pulmonary granulomas
surrounding ω1-mutated eggs was 18-fold smaller than wild type eggs. Programmed genome
editing was active in schistosomes, Cas9-catalyzed chromosomal breakage was repaired by
homology directed repair and/or non-homologous end joining, and mutation of ω1 impeded the
capacity of schistosome eggs both to drive Th2 polarization and to provoke formation of
pulmonary circumoval granulomas. Knock-out of ω1 and the impaired immunological phenotype
showcase the novel application of programmed gene editing in and functional genomics for
schistosomes.
60
61

Introduction

Schistosomiasis is considered the most problematic of the human helminth diseases in terms of morbidity and mortality [1-4]. The past decade has seen major advances in knowledge and understanding of the pathophysiology, developmental biology, evolutionary relationships and genome annotation of the human schistosomes [5-16]. Establishing CRISPR/Cas9 genome editing in schistosomiasis would greatly enable effective functional genomics approaches. The stable CRISPR/Cas9-based site-specific gene mutation and phenotyping will drive innovation and a deeper understanding of schistosome pathogenesis, biology and evolution [17].

The schistosome egg plays a central role both in disease transmission and pathogenesis [1]. The appearance of *S. mansoni* eggs in host tissues by six to seven weeks after infection coincides with profound polarization to a granulomatous, type 2 T helper cell (Th2) phenotype [18-22]. Numerous egg proteins have been characterized, with >1,000 identified in a well-studied fraction termed soluble egg antigen (SEA) [23-26]. In viable eggs, about 30 of the SEA proteins are located outside the developing miracidium and encompass the complement of secreted antigens (egg-secreted proteins, ESP) that interact with host tissues to facilitate the passage of the egg from the mesenteric veins to the intestinal lumen [27]. The T2 ribonuclease omega-1 (ω1) is the principal Th2-inducing component of ESP with its Th2-polarizing activity dependent upon both its RNase activity and glycosylation [19, 20, 28]. This RNase is hepatotoxic [29], and its secretion by eggs into the granuloma regulates the pattern recognition receptor signaling pathways in dendritic cells that, in turn, prime Th2 responses from CD4$^+$ T cells [30]. Secreted ω1 provokes granulomatous inflammation around eggs traversing the wall of the intestines, and trapped in hepatic sinusoids and other host organs, driving fibrosis that eventually results in hepatointestinal schistosomiasis [1, 31]. As ω1 drives distinctive immunological phenotypes including Th2 polarization and granuloma formation, we investigated, for the first time in schistosomes and indeed any flatworms, the use of programmed CRISPR/Cas9-mediated genome editing [32, 33] to alter the ω1 locus by both gene knockout and knock-in approaches. The investigation revealed that programmable genome editing catalyzed by the bacterial endonuclease Cas9 was active in schistosomes, with chromosomal double stranded breaks (DSB) repaired by homology recombination directed repair (HDR) using a donor, single stranded oligonucleotide template bearing short homology arms and/or by non-homologous end joining (NHEJ). The programmed mutagenesis decreased levels of ω1 mRNA and induced distinct *in vitro* and *in vivo* phenotypes, including a substantial loss of capacity of SEA from ω1-mutated eggs to polarize Th2 cytokine responses (IL-4 and IL-5) in co-cultured monocytic and T cells and loss of capacity to provoke formation of pulmonary granulomas *in vivo*. Functional knock-out of ω1 and the resulting immunologically impaired phenotype showcase the novel application of CRISPR/Cas9 and its utility for functional genomics in schistosomes.

Results

Omega-1, a multicopy locus on chromosome 1 of *S. mansoni* specifically expressed in eggs

The ω1 locus on chromosome 1 is repetitive and presents a challenge for genome assembly. Five genomic copies of ω1 were identified in the *S. mansoni* reference genome, versions 5 (Fig. S1). A single copy of ω1 selected for genome editing includes nine exons separated by eight introns and spans 6,195 nt (Smp_193860) (Fig. 1A). Several other copies have similar exon/intron structure, (Fig. S1) and conserved, predicted amino acid sequences. The predicted coding sequence (CDS) of Smp_193860 encodes an enzyme of ~31 kDa, as reported for ω1[34] and encodes a T2 ribonuclease with conserved CASI and CASII catalytic regions. We designed a sgRNA targeting residues 3808 to 3827 of the predicted exon 6 of Smp_193860, adjacent to the protospacer adjacent motif (PAM) AGG and with the predicted Cas9 cleavage site located at three residues upstream of this PAM. The AGG and the nucleotide sequence complementary to this sgRNA were present on two additional copies of ω1, Smp_179960 and Smp_184360. These shared >99% identity to Smp_193860 although the CDS of the three gene copies of ω1 differed by several substitutions (Fig. S2, panels A, B). Notably, the ω1 copies Smp_193860, Smp_179960 and Smp_184360 displayed an egg stage-specific expression profile without expression elsewhere throughout the developmental cycle of this schistosome (Fig. S1C) [35].

Homologous Recombination Directed Repair and Non-Homologous End Joining pathways in schistosomes

HDR and NHEJ pathways in schistosomes

The draft genome of *Schistosoma mansoni* genome was surveyed for key proteins of the non-homologous end joining (NHEJ) and homologous recombination directed repair (HDR) pathways. Artemis and DNA-PKcs are essential NHEJ factors in vertebrates [36, 37]. Candidate homologues for six of seven human NHEJ pathway genes and for two key HDR pathway genes, were identified by searching for matches to Pfam (Table S1). A putative homologue of Cernunnos/XLF was not apparent in *S. mansoni* [37] based on searching for the Pfam XLF domain (PF09302) found in human Cernunnos/XLF. The domain appears to be absent from all flatworm species studied by the International Helminth Genomes Consortium [38].

Site-specific integration of exogenous DNA confirmed CRISPR-Cas9 activity in schistosomes

The activity and efficiency of CRISPR/Cas9 to edit the schistosome genome, by targeting the ω1 locus, was explored using two approaches. First, a ribonucleoprotein complex (RNP) comprised of sgRNA mixed with recombinant Cas9 endonuclease was delivered into schistosome eggs isolated from livers of experimentally-infected mice (eggs termed 'LE', 'liver eggs') by electroporation. In addition, Homology Directed Repair (HDR) of CRISPR/Cas9-induced DSBs at the ω1 locus in the presence of a donor DNA template was investigated [39-41]. A single stranded oligodeoxynucleotide (ssODN) of 124 nt in length was delivered to some LE as a template for HDR of chromosomal double stranded breaks (DSBs) (Fig. 1B). The ssODN included a short transgene encoding six stop codons flanked by 5'- and 3'-homology arms, each

arm 50 nt in length, complementary to the genome sequence of exon 6 on the 5´ and 3´ sides of
the Cas9 cleavage site (Fig. 1A, B). In a second approach, a lentivirus vector (pLV-ω1X1; Fig.
1C) that included Cas9, driven by the mammalian translational elongation factor 1 promoter, and
the exon 6-targetting sgRNA (20 nt), driven by the human U6 promoter was engineered [42]. LE
were transduced with pseudotyped lentiviral virions (LV) by exposed in culture to LV for 24
hours [43] and, thereafter, transfected with the ssODN repair template. In both approaches,
expression of ω1 in LE after 72 hours in culture was ascertained.
155
Given that the donor ssODN included a short transgene that facilitates genotyping, PCR was
performed using template genomic DNAs from the CRISPR/Cas9-treated LE [39] to reveal the
site-specific knock-in (KI). A forward primer termed Smω1X1-6stp-cds-F specific for the
ssODN transgene was paired with three discrete reverse primers, termed Smω1-R1, Smω1-R2
and Smω1-R3, at increasing distance from the predicted HDR insertion site in ω1 (Table S2).
Amplicons of the expected sizes of 184, 285 and 321nt were observed in genome-edited eggs but
not in control eggs (Fig. 2A, B; Fig. S3A), a diagnostic pattern indicative of the ssODN
transgene insertion into *ω1* and, in turn, indicating that the resolution of the DSB at the *ω1* locus
from CRISPR/Cas9 had been mediated by HDR. Amplification using a control primer pair that
spanned the predicted DSB, termed Smω1-control-F/R, yielded control amplicons of the
expected 991 nt. Similar findings were observed with genome editing delivered by RNPs and by
LV (Fig. S3). Sanger sequence analysis of the knocked-in amplicons (KI-R1, KI-R2 and KI-R3)
confirmed the presence of the transgene inserted into the *ω1* locus at the site predicted for
programmed Cas9 cleavage (Fig. 2C).

Programmed mutations detected in exon 6 of *ω1*
171
The activity of CRISPR/Cas9 was first evaluated by a quantitative PCR (qPCR) approach that
relies on the inefficient binding of a primer overlapping the gRNA target, i.e. where mutations
are expected to have occurred, compared to the binding efficiency of flanking primers, i.e.
outside the mutated region [44, 45]. The overlapping (OVR) primer pair shared the reverse
primer with OUT primer (Fig. S4 A). Genomic DNA template was used for qPCR to quantify the
efficiency of CRISPR-mediated mutagenesis at the target locus; the ratio between the OVR
products and OUT products estimates the relative amplification fold reduction in CRISPR/Cas9-
manipulated samples compared to controls in the target sequence of the gRNA, i.e. the annealing
site for the OVR primer. Relative fold amplification was reduced by 12.5% was detected in
gDNA isolated from eggs treated with pLV-ω1X1 and ssODN whereas a reduction in relative
fold amplification of 2.5, 6.9, and 4.5 were observed in eggs treated with gRNA/Cas9 RNP
complex alone, gRNA/Cas9 RNP complex and ssODN, or pLV-ω1X1 alone, respectively. A
reduction in relative fold amplification was not apparent among control groups, i.e. untreated
eggs, eggs electroporated in the presence of Opti-MEM only, eggs transduced with heated-
inactivated pLV-ω1X1 with or without ssODN donor, and eggs transfected with ssODN only
(Fig. S4B).
188
To further characterize and quantify the mutations that arose in the genome of ω1 gene-edited
eggs, we used an amplicon-sequencing approach. Barcoded amplicon libraries were constructed
from pooled genomic DNA of six independent exposures of LE to pLV-ω1X1 and the donor
ssODN. Each amplicon was sequenced on the MiSeq Illumina platform and the CRISPResso
pipeline [46] was used to analyze deep-coverage sequence. More than 56 million sequenced

reads were compared to the reference sequence of the Smp_193860 locus (Table S3), which
revealed that 71% exhibited the wild type (WT, i.e. unmodified DNA) whereas 29 % reads
exhibited apparent mutations (Fig. 2D) across the 202 bp amplicon, with 0.13% insertions,
0.58% deletions and 28.2% substitutions (Table S3, sample 9). In contrast, in the control eggs-
only group, 76% were WT, and 24% of reads exhibited apparent mutations, with 0.14%
insertions, 0.33% deletions, and 24.0% substitutions (Fig. 2E; Table S3, sample 2 in Table S3).
Thus, subtracting the rate of apparent mutations in the control, we estimated that 0.25% and
4.2% of reads in the experimental sample carried programmed CRISPR-induced deletions and
substitutions, respectively. Indels of 1-2 bp, or multiples thereof, in coding DNA cause frame-
shifts, and consistent with its higher rate of indels, the CRISPR/Cas9-treated sample displayed a
higher rate of frame-shifts compared to a sample from control eggs (2.0% versus 1.4%; Table
S3).
206
Many apparent sequence variants common to the control and edited eggs likely reflect
polymorphism among copies of ω1 rather than programmed mutations. The sequence reads
revealed several common variants, such as adjacent 'TA' substitutions instead of 'CC' at
positions 152-153 of the amplicon, which encodes a change from Q to K at the amino acid level.
The gene Smp_193860 has 'TA' at this position in the V5 assembly [12], as does the mRNA
XP_018647487.1 from the NCBI database, whereas Smp_193860, Smp_184360 and
Smp_179960 all have 'CC' at this position in the V7 assembly (Berriman and co-workers, in
preparation) (Fig. S2 panels A, B), whereas 'CC' was also observed in KI fragments by Sanger
direct sequencing (Fig. 2C). Similarly, a second common dinucleotide substitution from 'AC' to
'TT' at positions 60-61 encodes an amino acid change from T to F. Both dinucleotide
substitutions occurred together in 8% of reads in the control group (Table S3, sample 2,) and 4%
of reads in the gene-edited sample (Table S3, sample 9). Both these non-synonymous
substitutions may have functional significance given their proximity to the catalytic site of the
ribonuclease (Fig. S2, panels C, D).
221
Along with the predicted NHEJ-catalyzed mutations, CRISPResso determined the rate of HDR-
mediated ssODN knock-in (Table S3; Fig. 2F). Here, insertion of the 24 bp transgene was
confirmed in 0.19% of the reads at the sgRNA programmed CRISPR/Cas9 target site (Fig. 2F;
sample 9 in Table S3). Some reads containing the knock-in sequence included the 'CC' to 'TA'
substitutions at positions 152-153 and 'AC' to 'TT' at positions 60-61 (Fig. S2; Table S3). This
indicates that the indels catalyzed by NHEJ and/or KI by HDR occurred in multiple copies of ω1
including Smp_193860, Smp_184360 and Smp_179960, and possibly also further copies not yet
annotated in the reference genome. The qPCR approach estimated a reduction by 12.5% in
relative fold amplification in the pLV-ω1X1 with ssODN treatment group (Fig. S4) whereas
CRISPResso analysis of the pooled NGS reads indicated a frequency of indel/substitution
mutation of ~4.5% (Table S3).

Programmed gene editing markedly reduced the expression of ω1
234
Liver eggs (LE) transfected with RNP complexes, without or with ssODN, displayed a down
regulation of the ω1-specific transcript of ~45% and 81%, respectively, compared to controls (p
≤ 0.05; $n = 11$). However, LE transduced with pLV-ω1X1 virions, without or with ssODN,
showed a reduction of the ω1-specific transcripts of 67% and 83% respectively, when compared
to controls (Fig. 3A). Similar outcomes were seen in all biological replicates undertaken ($n = 11$).

This outcome indicated that resolution of chromosomal DSB by NHEJ plus HDR provided
enhanced programmed gene knockout compared to NHEJ-mediated chromosomal repair alone.
Nevertheless, both RNPs and pLV virions efficiently delivered programmed gene editing to
schistosomes but lentiviral transduction delivered enhanced performance with stronger gene
silencing, in particular when the donor repair template was provided (Fig. 3A). When examined
at later time points (days 5 and 7 following manipulation of the LE), further reduction in ω1
abundance was not apparent (Fig. 3B).
247
248 Large DNA deletions have been associated with CRISPR/Cas9 mutations in another helminth
249 species [40]. However, using qPCR to estimate relative copy number, as previously described
250 [47], we found no evidence that silencing of ω1 was associated with a reduction in the copy
251 number of this multi-gene locus (Fig. S5).
252
253 **Diminished ribonuclease activity in CRISPR/Cas9 mutated Soluble Egg Antigen**
254
The ribonuclease activity of the ω1 glycoprotein in SEA is associated with the Th2-polarized
immune response that underpins the appearance of schistosome egg granulomata [19, 22].
Ribonuclease activity of SEA from control and experimental groups on substrate yeast RNA was
investigated following CRISPR/Cas9 programmed mutation of ω1 mediated by the RNP and the
pseudotyped lentiviral approaches with or without ssODN [20, 48]. Intact yeast RNA was
evident in the DNase-RNase free condition (negative control), indicative of absence of RNase
activity in the reagents (200 ng yeast RNA at the outset). There was near complete hydrolysis of
yeast RNA following exposure to RNase A (positive control); ~1.4 ng of RNA remained intact.
Wild type SEA exhibited marked RNase activity against the yeast RNA; ~70 ng RNA remained
intact after one hour, corresponding to >60% digestion. Incubation of the RNA with Δω1-SEA
from the experimental groups, RNP, RNP + ssODN, pLV-ω1X1, and pLV-ω1X1+ssODN,
resulted in ~30% substrate digestion, with 124, 140, 135 and 153 ng of RNA remaining,
respectively. All conditions for programmed genome editing resulted in less digestion of the
yeast RNA than for wild type SEA ($p \leq 0.0001$) (Fig. 3C, D). Moreover, the Δω1-SEA with
programmed knock-in exhibited less RNase activity than Δω1-SEA prepared without the donor
ssODN repair template ($p \leq 0.01$).
271
272 **Depleting SEA of ω1 down-regulated Th2 response**
273
The ω1 ribonuclease alone is capable of conditioning human monocyte-derived dendritic cells to
drive Th2 polarization [22] and enhanced CD11b[+] macrophage modulation of intracellular toll
like receptor (TLR) signaling [30]. Ribonuclease ω1 inhibited TLR-induced production of IL-1β
and redirected the TLR signaling outcome towards an anti-inflammatory posture via the mannose
receptor (MR) and dectin [22, 49, 50]. The human monocytic cell line, THP-1, and the Jurkat
human CD4[+] T cell line were employed to investigate the interaction of antigen presenting cells
and T cells [51, 52]. At the outset, the THP-1 cells were differentiated to macrophages for 48
hours, then pulsed with SEA or Δω1−SEA for 48 hours, after which the Jurkat CD4[+] T cells were
added to the wells. Subsequently, the co-culture continued for 72 hours. Representative
cytokines, including IL-4, IL-5, IL-13, IL-2, IL-6, IL-10, TNF-α and IFN-γ, were quantified in
supernatants of the co-cultures (Fig. 4). SEA from ω1-mutated eggs induced reduced levels of
Th2 cytokines, including IL-4 and IL-5, in comparison to wild type SEA ($p \leq 0.01$), and a trend

towards less IL-13 production was also observed (Fig. 4). Moreover, reduced levels of IL-6 and
TNF-α were observed ($p \leq 0.01$). By contrast, significant differences in levels of IL-10 and IL-2
were not evident between the WT- and mutant-SEA groups. IFN-γ was not detected following
pulsing with the WT-SEA or mutant-SEA (Fig S6).
290
291

292 **Granulomatous inflammation markedly reduced in lungs of mice injected with Δω1 eggs**
293

Following the entrapment of eggs in the intestines, liver and eventually lungs, the glycosylated
ω1 ribonuclease represents the principal stimulus that provokes the development of the
circumoval granuloma, necessary for extravasation of the eggs [53]. A long-established model of
the schistosome egg granuloma employs tail vein injection of eggs into mice, which leads to
formation of circumoval granuloma in the mouse lung [54-56]. The latter approach has been
extensively employed for immunopathogenesis-related studies of ω1 [16]. Accordingly, to elicit
circumoval granulomas, ~3,000 WT or Δω1 LE were injected into the lateral vein of the tail of
BALB/c mice. The mice were euthanized 10 days after injection, and the entire left lung was
removed, fixed, sectioned, and stained for histological analysis (Fig. 5). Representative digital
microscopic images of the whole mouse lungs acquired through high-resolution 2D digital scans
are presented in Figure 5, panels A-F. At low magnification (2×), severe and widespread
inflammation was visible in lungs exposed to WT eggs compared to Δω1 eggs. In addition,
markedly more intense and dense focal inflammation was induced by WT compared to Δω1 eggs
(Fig. 5A). Granulomas were not seen in control naïve mice not exposed to schistosome eggs
(Fig. 5C). At 20× magnification, considerable disparity in volume of the circumoval granulomas
was observed for WT versus Δω1 LE (Fig. 5A1-A2, 5D, 5E vs Figs. 5B1-B2, 5F, G). The
volume of granulomas surrounding single schistosome eggs was quantified; those surrounding
WT eggs in lungs of the mice were 18-fold greater than for Δω1 eggs, $21 \times 10^{-2} \pm 1.61 \times 10^{-3}$ mm^3
and $0.34 \times 10^{-2} \pm 0.12 \times 10^{-4}$ mm^3 (mean ± S.E., 17-26 granulomas per mouse), respectively ($P <$
0.0001) (Fig. 5H). The experiment was repeated with 3-4 mice per group with similar outcome.
The findings documented marked deficiency in the induction of pulmonary granulomas by the
Δω1 compared to WT eggs of *S. mansoni*.

GenBank/EMBL/DDBJ

Database accessions Sequence reads from the amplicon NGC libraries are available at the
European Nucleotide Archive, study accession number ERP110149. Additional information is
available at Bioproject PRJNA415471, https://www.ncbi.nlm.nih.gov/bioproject/PRJNA415471
and GenBank accessions SRR6374209, SRR6374210.
321

Discussion

Using *Schistosoma mansoni* as an exemplar, we have demonstrated the activity and feasibility of programmed CRISPR/Cas9 genome editing in the phylum Platyhelminthes. On-target genome editing was evidenced by site-specific mutations in the ω1 locus in chromosome 1. The chromosomal lesion induced by CRISPR/Cas9 was repaired by the non-homologous end joining (NHEJ) pathway [57] in the absence of a donor oligonucleotide and by homology directed repair (HDR) when a single stranded donor oligonucleotide was provided as the repair template [58-60].

The CRISPR/Cas9 components were successfully delivered to cultured schistosome eggs both using electroporation of a ribonucleoprotein particle (RNP) complex and using a lentiviral virion delivery system, in similar fashion to earlier reports in cell lines, tissues and entire organisms [61-64]. Delivery of RNPs provides the possibility for immediate editing, although the short half-life of the RNP components may be disadvantageous. Delivery of the CRISPR components on plasmids and by viral-mediated infection may provide sustained activity, transgene integration in non-dividing cells, and other attributes [33, 65]. Transfection by LV provides a hands-free approach to enable scaling of gene editing and the potential that less accessible and/or differentiated cells can be reached.

The genomic DNAs recovered from ~10,000 CRISPR/Cas9-treated LE would have included thousands of copies of the schistosome genome. We investigated the performance and efficiency of programmed genome editing by several approaches including NGS based analysis of pooled genomic DNAs of experimental and control groups of schistosome eggs. Analysis of the deep-coverage reads of amplicons spanning the predicted DSB site in the ω1 locus revealed that ~4.5% of the reads were mutated by insertions, deletions, and substitutions, The target locus was mutated by knock-in (KI) of a ssODN repair template bearing short homology arms to mediate homology directed repair following DSB at ω1, with an efficiency for HDR of 0.19% insertion of the donor transgene. The numerous substitutions compared to deletions and insertions were noteworthy. However, ω1 is a multi-copy gene and some apparent substitutions may reflect single nucleotide polymorphisms (SNPs) among the multiple gene copies.

The schistosome liver eggs (LE) exposed to genome editing spanned the spectrum of egg development, ranging from newly laid to fully mature [11]. When released from adult female schistosomes into the mesenteric veins, the ova each contain single celled zygotes surrounded by 30 to 40 vitelline cells [27]. By six or so days later, the miracidium within the eggshell is a mobile, ciliated larva comprised of organs, tissues, muscles and nerves [25, 66-68]. This investigation targeted the multicellular LE, and therefore our manipulations focused on somatic (rather than germ line) genome editing [65]. In addition, given the multicopy nature of ω1, the numerous cells in each of the schistosome eggs [66] the spectrum of development of these eggs, the diverse mutation profile of NHEJ, and the other contributions to variability (below), mosaicism of mutations were expected, i.e. some displayed HDR but not NHEJ, some NHEJ but not HDR, other cells and NHEJ and HDR, and many retained the wild type genotype. As well as the expected relative ease of access by the RNPs, virions and ssODN to the cells of syncytial inner envelope compared to the cells within the miracidium, other factors may have contributed to variability of CRISPR efficiency among the eggs and the cells within individual eggs. Cells exposed to CRISPR/Cas9 components may not have entered mitosis; HDR proceeds at cell division, with the cell at late S phase or G2 following completion of DNA replication where the

369   sister chromatid can act as the repair template [69]. Otherwise, NHEJ proceeds to repair the
370   DSB. Whereas incubating the eggs in virions would be expected to ensure that virions contacted
371   every egg, the coverage of infection was not assessed, and nor for the RNPs and the subsequent
372   transduction by ssODN.
373
Expression levels of ω1 were diminished by as much as 83% relative to controls suggesting that
Cas9 catalyzed the mutation of ω1, and that programmed Cas9-induced DSBs had been resolved
by NHEJ and/or HDR. Knock-in of the ssODN repair template induced 81-83 % reduction in
ω1-specific mRNA levels, whereas down regulation of 45 to 67 % followed the exposure of eggs
to RNP or lentivirus without ssODN. Notably, less than 5% efficiency in gene editing, based on
analysis of the NGS reads, appeared to account for this markedly reduced (>80%) gene
expression. The possibility of large-scale deletions, as reported in *Strongyloides stercoralis* [40],
offered one explanation for this apparent paradox. However, qPCR analysis of ω1 copy number
did not reveal apparent differences between treatments and controls. An alternative explanation
for the paradox may be the tight tissue specific expression of ω1, which not only is expressed
only in the egg developmental stage of *S. mansoni* (Fig. S1C) [70] and, moreover, only occurs
within the syncytial 'inner envelope' of squamous, epidermal-like cells surrounding the
miracidium [66]. Expression of ω1 appears to be tightly developmentally regulated [35]; based
on comparison of expression in the egg to expression in the miracidium, immunostaining and
transmission electron microscopy of the mature egg, all or most expression of ω1 takes place in
the mature egg and not in immature eggs or other larval or adult stages [20, 25, 27, 29, 71].
Within the mature egg, the fully developed miracidium is surrounded by a squamous, syncytial
epithelium termed variously as the envelope, the inner envelope, or von Lichtenberg's envelope
[25, 27, 66, 67]. This syncytial layer is metabolically active [27], and likely the site of synthesis
of T2 ribonuclease ω1 that is released from the egg [25, 27, 29], along with other secreted/
excreted proteins that help facilitate egress of the egg from the blood vessels and through the
wall of the intestine [27]. The virions may not have infected many of the cells within mature
eggs, because after entry into the egg the virus would be expected to contact the syncytial
envelope, rather than traveling further to directly contact cells of the miracidium. That is, the
efficiency of gene editing may not have been high across all cells of an egg but may (due to ease
of access to certain cells) have had highest efficiency in those cells in which ω1 is expressed.
This may explain the large reduction in ω1 transcripts in the CRISPR-treated eggs relative to the
control eggs.
402
Whereas wild type SEA polarized Th2 cytokine responses including IL-4 and IL-5 in human
macrophage/T cell co-cultures, significantly reduced levels of these cytokines were observed
when the cells were exposed to ω1-mutated SEA. Moreover, following introduction of eggs into
the tail vein of mice, pulmonary circumoval granulomas were substantially reduced in size
around $\Delta\omega$1 eggs compared to granulomas and the inflammation provoked by wild type eggs.
Whereas this outcome extends earlier findings using lentiviral transduction of eggs of *S. mansoni*
to deliver microRNA-adapted short hairpin RNAs aiming to silence expression of ω1 [16], the
reduction in granuloma volume was far more prominent in the present study. In addition to
incomplete disruption of all copies of ω1, residual granulomas around the mutant eggs may be
due to the presence of other Th2-polarizing components within SEA that have recently been
reported [72]. Given that the T2 ribonuclease ω1 is the principal, major type 2-polarizing protein

among egg-secreted proteins [19, 20], our findings of a phenotype characterized by the absence
or diminutive granulomas provide functional genomics support to this earlier advance [22].
416
The findings confirmed that somatic genome editing of schistosome eggs led to functional
knockout of the ω1 T2 ribonuclease, and mosaicism of mutant and wild type cells. The genome-
edited eggs exhibited loss of function of ω1 but remained viable. Programmed mutation of ω1
using CRISPR/Cas9 not only achieved the aim of establishing the applicability of genome
editing for functional genomics of schistosomes but also demonstrated manipulation of a gene
expressed in the schistosome egg, the developmental stage central to the pathophysiology of
schistosomiasis. This study provides a blueprint for editing other schistosome genes, and those of
trematodes and platyhelminths at large. The challenge for future studies is now to deliver
pseudotyped virions and programmed genome editing to the schistosome germ line. Mutant
parasite lines derived following this protocol [11, 73] will enable more comprehensive
understanding of the pathogenesis of this neglected tropical disease and accelerate the discovery
of novel strategies for parasite control.
429

Materials and Methods

Ethics statement

Mice experimentally infected with *S. mansoni*, obtained from the Biomedical Research Institute,
Rockville (BRI), MD were housed at the Animal Research Facility of the George Washington
University Medical School, which is accredited by the American Association for Accreditation
of Laboratory Animal Care (AAALAC no. 000347) and has an Animal Welfare Assurance on
file with the National Institutes of Health, Office of Laboratory Animal Welfare, OLAW
assurance number A3205-01. All procedures employed were consistent with the Guide for the
Care and Use of Laboratory Animals. The Institutional Animal Care and Use Committee of the
George Washington University approved the protocol used for maintenance of mice and
recovery of schistosomes. Studies with BALB/c mice involving tail vein injection of schistosome
eggs and subsequent euthanasia using overdose of sodium pentobarbitone was approved by the
IACUC of the Biomedical Research Institute (BRI), protocol 18-04, AAALAC no. 000779 and
OLAW no. A3080-01.

Schistosome eggs

Mice were euthanized seven weeks after infection with *S. mansoni*, livers were removed at
necropsy, and schistosome eggs recovered from the livers, as described [74]. The liver eggs
termed 'LE' were maintained in RPMI medium supplemented with 10% heat inactivated fetal
bovine serum (FBS), 2% streptomycin/penicillin and protease inhibitor cocktail (Sigma) at 37°C
under 5% CO_2 in air [73, 75]. Polymyxin B to 10 μg/ml was added to the cultures twice daily to
neutralize lipopolysaccharide (LPS) [76]. Soluble egg antigen (SEA) was prepared from these
eggs, as described [23, 54]. In brief, the homogenate of eggs in 1×PBS containing protease
inhibitor cocktail (Sigma) was frozen and thawed twice, clarified by centrifugation at 13,000
rpm, 15 min, 4°C, the supernatant passed through a 0.22-μm pore size membrane. Protein
concentration of the supernatant (SEA) were determined by the Bradford Protein Assay [77] and
aliquots of the SEA stored at -80°C.

Guide RNAs, Cas9, and single stranded DNA repair template

Single guide RNA (sgRNA) was designed using the web-based tools at

http://bioinfogp.cnb.csic.es/tools/breakingcas/ [78] to predict cleavage sites for the *Streptococcus*

pyogenes Cas9 nuclease within the genome of *S. mansoni*. The sgRNA targeted exon 6 of the *ω1*

gene, Smp_193860, www.genedb.org, residues 3808-3827, adjacent to the protospacer adjacent

motif, AGG (Fig. 1A). This is a multi-copy gene with at least five copies of *ω1* located in

tandem on chromosome 1 [12]. To infer the gene structure of Smp_193860 in the *S. mansoni* V5

assembly more accurately, the omega-1 mRNA DQ013207.1 sequenced by Fitzsimmons *et al*.

(2005) [29] was used to predict the gene structure with the exonerate software, by aligning it to

the assembly using the exonerate options '--model coding2genome' and '--maxintron 1500'. The

Smp_193860 copy of *ω1* includes nine exons interspersed with eight introns (6,195 nt) (Fig. 1A).

Synthetic gRNA (sgRNA), *ω1*-sgRNA was purchased from Thermo Fisher Scientific (Waltham,

MA). A double stranded DNA sequence complementary to the sgRNA was inserted into

lentiviral gene editing vector, pLV-U6g-EPCG (Sigma), which encodes Cas9 from *S. pyogenes*

driven by the eukaryotic (human) translation elongation factor 1 alpha 1 (tEF1) promoter and the

sgRNA driven by the human U6 promoter (Fig 1C). (The pLV-U6g-EPCG vector is tri-cistronic

and encodes the reporter genes encoding puroR and GFP, in addition to Cas9 [79].) This gene-

editing construct, targeting exon 6 of *ω1* Smp_193860, was termed pLV-ω1X1. A single

stranded oligodeoxynucleotide (ssODN), which included homology arms of 50 nt each in length

at the 3' (position 3774-3824 nt) and 5'(3825-3874 nt) flanks and a small transgene (5'-

<u>TAA</u>G<u>TGA</u>CT<u>AGG</u>T<u>AAC</u>T<u>GAG</u>TAG-3', encoding stop codons (six) in all open-reading

frames) (Fig. 1B), was synthesized by Eurofin Genomics (KY, USA). An oligonucelotide primer

that included this sequence was employed in PCRs to investigate the presence of CRISPR/Cas9-

programmed insertion of the transgene [80] (Table S2).

Transfection of schistosome eggs with a Cas9/guide RNA complex

For the ribonucleoprotein (RNP) complex of the *ω1*-sgRNA and recombinant Cas 9 from

Streptococcus pyogenes, 3 μg of ω1-sgRNA and 3 μg of Cas9-NLS nuclease (Dharmacon,

Lafayette, CO) were mixed in 100 μl Opti-MEM (Sigma) to provide 1:1 ratio w/w RNP. The

mixture was incubated at room temperature for 10 min, pipetted into a 4 mm pre-chilled

electroporation cuvette containing ~10,000 LE in ~150 μl Opti-MEM, subjected to square wave

electroporation (one pulse of 125 volts, 20 milliseconds) (BTX ElectroSquarePorator, ECM830,

San Diego, CA). The electroporated eggs were incubated for 5 min at room temperature, and

maintained at 37°C, 5% CO_2 in air for 3, 5 and 7 days. To investigate whether homology-

directed repair (HDR) could catalyze the insertion of a donor repair template, 3 μg ssODN was

mixed with RNP and the LE before electroporation. In a second approach (above), the ssODN

was delivered to LE by electroporation at ~24 hours after the lentiviral transduction of the LE.

The eggs were collected 3, 5 and 7 days later and genomic DNA recovered from LE. The

negative controls included LE subjected to electroporation in the presence of only Opti-MEM,

only Cas 9, only sgRNA, and only ssODN.

Transduction of schistosome eggs with lentiviral particles

Escherichia coli Zymo 5α (Zymo Research) cells were transformed with lentiviral plasmid pLV-

ω1X1 and cultured in LB broth in 100 μg/ml ampicillin at 37°C, agitated at 225 rpm for ~18

hours, after which plasmid DNA was recovered (GenElute Plasmid purification kit, Invitrogen).

A lentiviral (LV) packaging kit (MISSION, Sigma-Aldrich) was used to prepare LV particles in

producer cells (human 293T cell line). In brief, 2.3×10^5 of 293T cells/well were seeded 6-well

tissue culture plate in DMEM supplemented with 10% heat- inactivated fetal bovine serum

(FBS), 2 mM L-glutamine, 2% penicillin/streptomycin and cultured at 37°C, 5% CO_2 for 18

hours. The producer cells were transfected using FUGENE 6 (Promega) with pLV-ω1X1 and LV

packaging mix containing two additional plasmids; one plasmid that expressed HIV structural

and packaging genes and another that expressed the pseudotyping envelope protein Vesicular

Stomatitis Virus Glycoprotein (VSVG). Subsequently, the transfection mixture (37.5 μl; 500 ng

plasmid DNA, 4.6 μl packaging mix, 2.7 μl of FUGENE 6 in Opti-MEM) was dispensed drop

wise into each well on the plate. Sixteen hours later, the media were removed from the

transfected cells, replaced with pre-warmed complete DMEM, and cells cultured for 24 hours.

The supernatant, containing VSVG-pseudotyped LV particles was filtered through 22 μm pore

size membranes [43], and stored at 4°C. Additional pre-warmed complete DMEM was added to

the well, for culture for a further 24 hours. The supernatant was collected as above, combined

with the first supernatant and concentrated (Lenti-X concentrator, Takara Bio, Mountain View,

CA). Virion titer was estimated by two methods; first, by use of Lenti-X-GoStix (Takara Bio) to

establish the presence of functional virions at $>10^5$ infectious units (IFU)/ml, and second, by

reverse transcriptase assay [43, 81] to quantify levels of active virions. Virions with counts of

$\sim4\times10^6$ count per minute (cpm)/ml were aliquoted and stored at -80°C.

To transduce LE with LV, ~10,000 eggs were incubated for 24 hours in complete DMEM

containing 500 μl of $\sim4\times10^6$ cpm/ml VSVG-LV virions. Thereafter, the LE were washed three

times in 1×PBS and transfected with ssODN by square wave electroporation or further steps. LV

virions heat-inactivated by incubation at 70°C for two hours [43] with subsequent transfection

with the ssODN, transfection with ssODN in the absence of virions or Opti-MEM only served as

negative controls.

PCR amplification of diagnostic transgene to detect knock-in into exon 6 of *ω1*

For each DNA sample, four separate PCR assays using four distinct primer pairs (Table S2) were

carried out. The first ω1 primer pair, to amplify locations 3751-4740 nt of Smp_193860, was

employed as positive control for the presence of genomic DNA with the Smp_193860 copy of

ω1. The other primer pairs shared one forward primer complementary to the knock-in 24 nt

transgene with three reverse primers, Sm ω1-R1, -R2 and -R3 at positions 3966-3984, 4066-4085

and 4102-4121 nt, respectively, binding to three sites downstream the ω1 predicted DSB site

(Fig. 2A; Table S2) [80]. The PCR mix included 10 μl Green GoTaq DNA polymerase mix

(Promega) with 200 nM of each primer and 10 ng genomic DNA. Thermal cycling conditions

involved denaturation at 95°C, 3 min followed by 30 cycles of 94°C, 30 sec, 60°C, 30 sec and

72°C, 30 sec and a final extension at 72°C for 5 min. Following agarose gel electrophoresis

(1.2% agarose/TAE), amplicons of the expected sizes were recovered from gels and ligated into

pCR4-TOPO (Thermo Fisher). *E. coli* Zymo 5α competent cells were transformed with the

ligation products, several colonies of each transformant were grown under ampicillin selection,

plasmid DNA purified, and insert sequenced to confirm the presence and knock-in of the

transgene (Fig. 1C).

Illumina sequencing

Pooled LE DNA samples from six independent KI experiments of pLV-ω1X1 with ssODN were

used as the template to amplify the on-target DNA fragment using MiSeq primers (Fig. 2A) with

High Fidelity *Taq* DNA polymerase (Thermo Fisher). PCR reactions were set up with 10 ng LE
DNA samples from the KI experiment in 25 µl reaction mix using the HiFidelity Taq DNA
polymerase (Thermo Fisher) following the PCR program 94ºC for 3 minutes of denaturation
followed by 30 cycles of 94ºC for 30 seconds, 60ºC or 54ºC or 30 seconds, 72ºC 45 seconds and
final extension at 72ºC for 2 minutes. The expected size of the amplicon flanking predicted DSB
was 205 bp. Amplicons of this size were purified by Agencourt AMPure XP (Beckman Coulter),
amplicons generated from four different PCR reactions from each sample were pooled, and 100
ng of amplicons from each sample used to construct the uniquely indexed paired-end read
libraries using the QIAseq 1-step Amplicon Library Kit (Qiagen) and GeneRead Adapter I set A
12-plex (Qiagen). These libraries were pooled, and the library pool was quantified using the
QIAseq Library Quant System (Qiagen).

555
Samples (10) (Table S3) were multiplexed and each run on four MiSeq lanes. After sequencing,
the fastq files for each particular sample were merged. Samples 1-6, 8 and 10 were prepared
using an annealing temperature of 54ºC. Samples 7 and 9 were prepared using an annealing
temperature of 60ºC, and included an extra 10 bp at the start of the MiSeq sequences,
'GTTTTAGGTC', present upstream of the 5' primer in the genomic DNA. We trimmed this
sequence from the reads using cutadapt v1.13 [82]. To detect HDR events, CRISPResso v1.0.9
[46, 83] was employed using a window size of 500 bp (-w 500) with the reference amplicon
according to gene *Smp_193860* in the *S. mansoni* V7 assembly, and with the --
exclude_bp_from_left 25 and --exclude_bp_from_right 25 options in order to disregard the (24
bp) primer regions on each end of the amplicon when indels are being quantified. A window size
of 500 nt was employed to include the entire amplicon. In order to search for HDR events,
CRISPResso checked for HDR events (using –e and –d options) in treatment groups including
controls. To infer frameshifts using CRISPResso the –c option was used, giving CRISPResso the
coding sequence from positions 42-179 of the amplicon. To confirm the insertions of the knock-
in sequences reported by CRISPResso (column L in Table S3), we took all insertions of 20-28 bp
reported by CRISPResso, and calculated their percent identity to the expected knock-in sequence
using ggsearch v36.3.5e in the fasta package [84], and an insertion was considered confirmed if
it shared ≥75% identity to the expected donor knock-in sequence.

Copy number estimation for ω1

A quantitative PCR to estimate the relative copy number of ω1 was performed using Kapa qPCR
mastermix SYBRfast (KK4602) on 1 ng of gDNA templates isolated from control and test
samples, in 20 µl volumes. Primer pair OMGgRNA1F and OMGgRNA1R was used to amplify
the ω1 gRNA target region and SmGAPDH (Smp_056970) as reference single-copy gene
(primers shown in Table S2). The PCR efficiencies for primer pairs were estimated by titration
analysis to be 100% ±5 [85] and qPCRs were performed in triplicate in 96-well plates, with a
denaturation step at 95°C of 3 min followed by 40 cycles of 30 s at 95°C and 30 s at 55°C, in
thermal cycler fitted with a real time detector (StepOnePlus, Applied Biosystem). The relative
quantification assay $2^{-\Delta\Delta Ct}$ method [86] was used to ascertain the relative copy number of ω1.
Relative copy number of ω1 copy number in the CRISPR/Cas9 treated groups reflects the fold
change of ω1 copy number normalized to the reference gene (Sm GAPDH) and relative to the
untreated control group (calibrator sample with relative ω1 copy number = 1) [47].

Gene expression for *ω1* mRNA

Total RNAs from schistosome eggs were extracted using the RNAzol RT reagent (Molecular
Research Center, Inc), which eliminates contaminating DNA [87], and concentration and purity
determined using a spectrophotometer ($OD_{260/280}$ ~2.0). Reverse transcription (RT) of the RNA
(500 ng) was performed using iScript Reverser Transcript (Bio-Rad), after which first strand
cDNA was employed as template for qPCRs using SsoAdvanced Universal SYBR Green
Supermix (Bio-Rad) performed in triplicates in a iQ5 real time thermal cycler (Bio-Rad). RT-
qPCR reaction mixtures included 2 µl first stand cDNA, 5 µl SsoAdvanced universal SYBR
Green Supermix, and 300 nM schistosome gene specific primers. Table S2 provides details of
the oligonucleotide primers. Thermal cycling included denaturation at 95°C for 30 sec, 40
amplification cycles each consisting of denaturation at 95°C for 15 sec and annealing/extension
at 60°C for 30 sec, and a final melting curve. The output was analyzed using the iQ5 software.
Relative expression of calculated using the $2^{-\Delta\Delta Ct}$ method and normalized to schistosome GAPDH
expression [86]; data are presented as transcript levels (three replicates) compared to the WT
(100%) LE, and fold change reported as mean relative expression ± SD.

RNase activity of ω1

A stock solution of yeast RNA (Omega Bio-tek, Norcross, GA) was prepared at 1.0 µg/µl, 50
mM Tris-HCl, 50 mM NaCl, pH 7.0. Yeast RNA (200 ng) was incubated with 2 µg SEA from
control and experimental groups individually at 37°C for 60 min. (SEA investigated here, named
Δω1-SEA, was extracted LE transduced with pLV- ω1X1 virions and ssODN, pooled from six
biological replicates.) RNase A, an endoribonuclease from bovine pancreas (Thermo Fisher)
served as a positive control enzyme whereas yeast RNA in reaction buffer only served as the
negative control. The RNase activity of ω1 in wild type SEA or Δω1-SEA was analyzed by
visualizing and quantifying the substrate that remained following enzymolysis by agarose gel
electrophoresis and staining with ethidium bromide. The yeast RNA digestion by control SEAs
or Δω1-SEA were set up in triplicates, with quantity of residual RNA determined by
densitometry [48].

Macrophage polarization by WT or Δω1-SEA and T-cell activation *in vitro*

Human monocytic THP-1 cells were maintained in Roswell Park Memorial Institute medium
(RPMI) 1640 with L-glutamine, HEPES (Thermo Fisher Scientific) containing 10% (v/v) FBS
with 4 mM glutamine, 25 mM HEPES, 2.5 g/L D-glucose at 37°C in 5% CO_2 in air. THP-1 cells
were non-adherent cells. In a 6-well plate, THP-1 monocytes (3×10^5 cells in each well) were
differentiated into macrophages (Mφ) by incubation in 150 nM phorbol 12-myristate 13-acetate
(PMA) (Sigma) for 48 hours [88]. Mφ were exposed to SEA (50 ng/ml) or Δω1-SEA (50 ng/ml)
(from LE transduced with pLV-ω1X1 virions and ssODN) for 48 hours. To investigate
macrophage and T cell interactions, Mφ cells were pulsed with 50 ng/ml SEA or Δω1-SEA and
thereafter co-cultured in direct contact with Jurkat (human $CD4^+$ T) cells. Nine $\times10^5$ Jurkat were
added to Mφ and direct contact, co-cultured for an additional 72 hours. Cell-free supernatants
from the co-cultures were collected to quantify secretion of T helper cell cytokines including IL-
4, IL-5, IL-13, IL-10, TNF-α, IL-6, IL-2 and IFN-γ by enzyme linked immunosorbent assay
(ELISA) (Qiagen) [89]. The assay included positive controls for each analyte, which were
provided in the ELISA kit (Qiagen). Three biological replicates were undertaken.

Schistosome egg-induced primary pulmonary granulomas

For induction of circumoval, egg-induced granulomas in the lungs of mice, 8 week old female
[25] BALB/c mice were injected with 3,000 WT egg or Δω1-egg or 1×PBS as negative control
by tail vein, as described [56]. The mice (6-9 mice/group) were euthanized 10 days later. For
histopathological assessment of granuloma formation, the left lung was removed at necropsy and
fixed in 10% formalin in pH 7.4 buffered saline for 24 hours, after which it was dehydrated in
70% ethanol, and clarified in xylene. The fixed lung tissue was embedded in paraffin and
sectioned at 4-μm-thickness by microtome [56]. Thin sections of the left lung lobe were mounted
on glass slides and fixed at 58-60°C. Subsequently, rehydrated sections were stained with
hematoxylin-eosin (H&E) for evaluation of inflammatory infiltrates and cellularity of
granulomas. The longest (R) and shortest (r) diameters of each granuloma containing a single
egg were measured with an ocular micrometer, and the volume of the granuloma calculated
assuming a prolate spheroidal shape, using $4/3\ \pi\ Rr^2$ [25]. All granulomas in all slides from the
left lung of the mice, 15 slides per treatment group, were measured; in total, >100 granulomas
from each treatment group. Digital images were captured using a 2D glass slide digital scanner
(Aperio Slide Scanner, Leica Biosystems, Vista, CA) and examined at high magnification using
the Aperio ImageScope (Leica) software [55, 90].

Statistics

647   Means for experimental groups were compared to controls by one-way ANOVA and, where
648   appropriate, by two-tailed Student's *t*-test and Welch's unequal variances *t*-test (GraphPad
649   Prism, La Jolla, CA). Values for *p* of ≤ 0.05 were considered to be statistically significant.

Acknowledgements

We thank Dragana Jankovic, Alan Sher, Thomas Wynn, Michael Bukrinsky, Larisa Dubrovsky,
Arnon Jurberg, Robert Thompson, Thiago De Almeida Pereira, Meredith Brindley and Luca
Pinello for advice and technical assistance. Schistosome-infected mice and snails were provided
by the NIAID Schistosomiasis Resource Center of the Biomedical Research Institute, Rockville,
Maryland through NIH-NIAID Contract HHSN272201000005I for distribution through BEI
Resources. These studies were supported by Wellcome Trust Strategic Award number
107475/Z/15/Z (Hoffmann, K.F., principal investigator), award R21AI109532 (GR, PJB) award
from NIAID, National Institutes of Health, Wellcome Trust grant WT 098051 and, in part, by
generous support from MaxMind Inc./TJ Mather.

       Figure legends

Figure 1. Genomic structure of the locus encoding omega-1 (ω1) in the genome of
Schistosoma mansoni, **guide RNA and CRISPR/Cas9 encoding construct.** Gene model of *ω1*
(Smp_193860), showing the position of its nine exons, eight introns and UTRs 6,195 bp on
chromosome 1 (panel **A**). Nucleotide sequence in exon 6 indicating location and sequence of
gRNA target site, predicted double stranded break (DSB) (arrow), protospacer adjacent motif
(PAM) (AGG, blue box), and 124-nucleotide sequence of the single stranded DNA donor
template provided for DSB repair by homologous recombination. Homology arms of 50 nt span
a central 24 nt of six-stop-codon transgene (**B**). Linear map of pLV-ω1X1 showing position of
regulatory and coding regions for CRISPR/Cas9 editing; the positions of human U6 promoter to
drive gRNA, translational elongation factor EFα-1 promoter driving Cas9 from *Streptococcus*
pyogenes, and the left and right long terminal repeats of the lentiviral vector derived from HIV-1
(**C**).

Figure 2. Programmed chromosomal break at *ω1* locus repaired by homologous
recombination from donor template. Schematic diagram to indicate positions of primer
binding sites (blue arrows), with the foreign gene cassette as the forward primer (Smω1X1-6-
stop codons cassette-F) paired with three discrete reverse primers, Smω1-R1, Smω1-R2 and
Smω1-R3 from the *ω1* locus and a primer pair for target amplicon NGS library amplification;
miSeq-F and miSeq-R (panel **A**). The control PCR amplicon was generated using the Sm**ω**1-
control-F and –R primers. The green box shows the location of 5' and 3' homology arms, red
box and arrow indicate the stop codon bearing transgene. **B**, PCR products visualized in ethidium
bromide-stained agarose gel demonstrating Cas9-catalyzed target site-specific insertional
mutagenesis in exon 6 of the *ω1* gene. Evidence for transgene knocked-in into programmed
target site revealed by amplicons of the expected sizes in lanes R1, R2 and R3, of 184, 285 and
321 bp, respectively (arrows at left) spanned the mutated site in the genomic DNAs pooled from
schistosome eggs, including a positive control flanking the insert site (991 bp). The control
DNA result shown in this gel was isolated from heat inactivated-pLV-ω1X1 virions and ssODN
treated LE. Similar findings were obtained when programmed gene editing was executed by
lentiviral virion-delivered Cas9 and *ω1*-gRNA transgenes and by ribonucleoprotein complex
(RNP) delivered by square wave electroporation (supporting information). The non-KI control
groups (sgRNA only, heat-inactivated pLV-ω1X1 virions only, ssODN only) showed no
amplicons by stop cassette-KI primers with R1, R2 or R3 (Fig. S4). **C**, Multiple sequence
alignments confirmed the presence of the 24 nt transgene inserted precisely into the exon 6 of *ω1*
locus from KI-R1, -R2 and -R3 fragments compared with *ω1* wild type (WT). The white box on
ω1-WT indicates the absence of the transgene sequence and white boxes on KI-R1, -R2 and –R3
fragments show locations of substitutions relative to the other *ω1* copies (Smp_184360): 2 bp
(AT to CC) mismatches at positions 253-254 nt. All three contained the (knock-in) insertion
sequence (white box), which confirmed targeted mutation of the *ω1* gene. **D-F.** Illumina deep
sequence analysis of amplicon libraries revealed Cas9 induced on-target repair of programmed
gene mutation of the *ω1* locus by deletions, insertions, and substitutions by CRISPResso
analysis. **D**. Frequency distribution of position-dependent deletions and of deletion sizes; these
varied from point mutations to >20 bp adjacent to the DSB. The dotted line indicates the
predicted position of the programmed double stranded break. **E.** Frequency of frameshift versus
in-frame mutations reported by CRISPResso**.** The pie charts show the fraction of all mutations

(indels and substitutions) in the coding region (positions 42-179) of the amplicon predicted to
induce frameshifts, i.e. indels of 1-2 bp, or multiples thereof. (a) corresponds to sample 2 (eggs
only control) (Table S3), (b) corresponds to sample 9 (eggs exposed to virions and ssODN, i.e.
CRISPR/Cas9-treated) (Table S3). Findings for control and treated samples are provided in
Table S3. **F.** Insertions of the knock-in sequence. Number of amplicon reads containing an
insertion of the knock-in sequence (with ≥75% identity to it) is shown in the Y-axis, and the
position of the insertion relative to the reference amplicon is shown on the X-axis. The
programmed Cas9 scission lies between positions 102 and 103. Samples 3, 7 and 9 are
independent amplicon libraries (technical replicates) made from the same sample of genomic
DNAS pooled from six biological replicates exposed to virions and ssODN. The insert shows a
sequence logo, created using WebLogo [91], of the sequences of the 3,826 sequence reads from
samples 3, 7 and 9, with insertions of 24 bp at position 102; most matched the donor template,
TAAGTGACTAGGTAACTGAGTAGC.
721
Figure 3. Diminished *ω1*-specific transcript levels and ribonuclease T2 activity following
programmed editing. Panel **A.** ω1 mRNA abundance was reduced up to ~ 70% after genome
editing by sgRNA/Cas9 complex and lentivirus systems, and markedly reduced >80% with the
addition of ssODN as the DNA repair donor. Relative expression of *ω1* transcripts at three days
following CRISPR/Cas manipulation; mean ±SD, n =11 (biological replicates); $p \leq 0.0001$
(****) (*n*=11) (ANOVA)..**B.** Stable reduction of *ω1* transcripts at days 5 and 7 after treatment
(three biological replicates) in four experimental groups; RNP (black), RNP and ssODN (red),
pLV-ω1X1 virions (green), pLV-ω1X1 virions and ssODN (blue) compared to controls. **C. Loss**
of RNase activity as assessed by hydrolysis of yeast RNA. Residual yeast following exposure to
SEA, visualized after gel electrophoresis; lane 1, buffer (negative control); 2, RNase A; 3-8, WT
SEA and other control SEAs as indicated in D; 9-12, Δω1-SEA from RNP, RNP and ssODN,
pLV-ω1X1 virions, and pLV-ω1X1 virions and ssODN, respectively. **D.** Intact yeast RNA
(nanograms) remaining following incubation with SEA (mean ±SD, *n* = 6). More RNA remained
following incubation with Δω1-SEA in all groups, RNP, RNP and ssODN, pLV-ω1X1 virions,
and pLV-ω1X1 virions and ssODN treated SEA) (blue) than in the WT SEA controls ($p \leq$
0.0001). Among the gene edited experimental groups, more RNA remained when donor template
was introduced at the same time as RNP or pLV-ω1X1 virions ($p \leq 0.01$). Significant differences
were not apparent among the WT SEA control groups.
740
Figure 4. Reduced Th2 cytokine levels following exposure to Δω1-SEA. Panel **A.** Reduction
in Th2 cytokines IL-4 and IL-5 but not IL-13 [92, 93] following pulsing of Mϕ (PMA induced-
THP-1 cells) with Δω1-SEA prior to co-culture with human CD4[+] T cells (Jurkat cell line)
compared with WT-SEA pulsed-Mϕ (top panels). In addition, levels of IL-6 and TNF-α were
reduced where Mϕ were first pulsed with Δω1-SEA but not WT SEA. Differences were not
evident for IL-10. The assay was carried out in triplicate; $p < 0.0001, \leq 0.0001, 0.0038$ and
0.0252 indicated as ****, ***, ** and *, respectively (one-way ANOVA, multiple comparison).
748
749 **Figure 5. Pulmonary circumoval granulomas revealed attenuated granulomatous response**
750 **to Δω1 schistosome eggs.** Schistosome eggs (~3,000 eggs) that had been transduced with
751 lentivirus virions encoding ω1-specific sgRNA and Cas9 in tandem with ssODN were introduced
752 via the tail vein into mice. The mice were euthanized 10 days later; thin sections of the left lung
753 were stained with H&E, and circumoval granulomas counted and measured. Representative 2D

scanned micrographs of granulomas inoculated with WT eggs (panel **A**) (2× magnification) and
20× magnification (a1 and a2), and with Δω1 eggs; **B** (2×), b1 and b2 (20×). **C**. Control mouse
lung. **D, E.** Representative micrograph of individual, control egg induced-granuloma that were
counted to assess for granuloma volume. **F, G**. Representative micrographs showing Δω1 egg
induced-granulomas. All single egg induced-granuloma from WT and Δω1 eggs were measured
and granuloma volume estimated [25]. **H.** Scatter plots of the volume (mm^3) for individual
granuloma, mean ± SE (red) is shown. Granulomas induced by Δω1 eggs were significantly
smaller than those surrounding WT eggs (Welch's *t*-test, $p \leq 0.0001$, $n > 100$).

References

1. Gryseels B, Polman K, Clerinx J, Kestens L: **Human schistosomiasis.** *Lancet* 2006, **368:**1106-1118.

2. Hotez PJ, Brindley PJ, Bethony JM, King CH, Pearce EJ, Jacobson J: **Helminth infections: the great neglected tropical diseases.** *J Clin Invest* 2008, **118:**1311-1321.

3. Hotez PJ, Alvarado M, Basanez MG, Bolliger I, Bourne R, Boussinesq M, Brooker SJ, Brown AS, Buckle G, Budke CM, et al: **The global burden of disease study 2010: interpretation and implications for the neglected tropical diseases.** *PLoS Negl Trop Dis* 2014, **8:**e2865.

4. Colley DG, Bustinduy AL, Secor WE, King CH: **Human schistosomiasis.** *Lancet* 2014, **383:**2253-2264.

5. Berriman M, Haas BJ, LoVerde PT, Wilson RA, Dillon GP, Cerqueira GC, Mashiyama ST, Al-Lazikani B, Andrade LF, Ashton PD, et al: **The genome of the blood fluke Schistosoma mansoni.** *Nature* 2009, **460:**352-358.

6. Schistosoma japonicum Genome S, Functional Analysis C: **The Schistosoma japonicum genome reveals features of host-parasite interplay.** *Nature* 2009, **460:**345-351.

7. Young ND, Jex AR, Li B, Liu S, Yang L, Xiong Z, Li Y, Cantacessi C, Hall RS, Xu X, et al: **Whole-genome sequence of Schistosoma haematobium.** *Nat Genet* 2012, **44:**221-225.

8. Lepesant JM, Grunau C, Cosseau C: **Towards an understanding of the epigenetics of schistosomes: a comparative epigenomic study.** *Mem Inst Oswaldo Cruz* 2011, **106:**823-830.

9. Geyer KK, Rodriguez Lopez CM, Chalmers IW, Munshi SE, Truscott M, Heald J, Wilkinson MJ, Hoffmann KF: **Cytosine methylation regulates oviposition in the pathogenic blood fluke Schistosoma mansoni.** *Nat Commun* 2011, **2:**424.

10. Vanderstraete M, Gouignard N, Cailliau K, Morel M, Hahnel S, Leutner S, Beckmann S, Grevelding CG, Dissous C: **Venus kinase receptors control reproduction in the platyhelminth parasite Schistosoma mansoni.** *PLoS Pathog* 2014, **10:**e1004138.

11. Rinaldi G, Eckert SE, Tsai IJ, Suttiprapa S, Kines KJ, Tort JF, Mann VH, Turner DJ, Berriman M, Brindley PJ: **Germline transgenesis and insertional mutagenesis in Schistosoma mansoni mediated by murine leukemia virus.** *PLoS Pathog* 2012, **8:**e1002820.

12. Protasio AV, Tsai IJ, Babbage A, Nichol S, Hunt M, Aslett MA, De Silva N, Velarde GS, Anderson TJ, Clark RC, et al: **A systematically improved high quality genome and**

807   transcriptome of the human blood fluke Schistosoma mansoni. *PLoS Negl Trop Dis*
808   2012, **6:**e1455.

809   13.   Valentim CL, Cioli D, Chevalier FD, Cao X, Taylor AB, Holloway SP, Pica-Mattoccia L,
810   Guidi A, Basso A, Tsai IJ, et al: **Genetic and molecular basis of drug resistance and**
811   **species-specific drug action in schistosome parasites.** *Science* 2013, **342:**1385-1389.

812   14.   Wang B, Collins JJ, 3rd, Newmark PA: **Functional genomic characterization of**
813   **neoblast-like stem cells in larval Schistosoma mansoni.** *Elife* 2013, **2:**e00768.

814   15.   Collins JJ, 3rd, Wang B, Lambrus BG, Tharp ME, Iyer H, Newmark PA: **Adult somatic**
815   **stem cells in the human parasite Schistosoma mansoni.** *Nature* 2013, **494:**476-479.

816   16.   Hagen J, Young ND, Every AL, Pagel CN, Schnoeller C, Scheerlinck JP, Gasser RB,
817   Kalinna BH: **Omega-1 knockdown in Schistosoma mansoni eggs by lentivirus**
818   **transduction reduces granuloma size in vivo.** *Nat Commun* 2014, **5:**5375.

819   17.   Hoffmann KF, Brindley PJ, Berriman M: **Medicine. Halting harmful helminths.**
820   *Science* 2014, **346:**168-169.

821   18.   Pearce EJ, MacDonald AS: **The immunobiology of schistosomiasis.** *Nat Rev Immunol*
822   2002, **2:**499-511.

823   19.   Steinfelder S, Andersen JF, Cannons JL, Feng CG, Joshi M, Dwyer D, Caspar P,
824   Schwartzberg PL, Sher A, Jankovic D: **The major component in schistosome eggs**
825   **responsible for conditioning dendritic cells for Th2 polarization is a T2 ribonuclease**
826   **(omega-1).** *J Exp Med* 2009, **206:**1681-1690.

827   20.   Everts B, Perona-Wright G, Smits HH, Hokke CH, van der Ham AJ, Fitzsimmons CM,
828   Doenhoff MJ, van der Bosch J, Mohrs K, Haas H, et al: **Omega-1, a glycoprotein**
829   **secreted by Schistosoma mansoni eggs, drives Th2 responses.** *J Exp Med* 2009,
830   **206:**1673-1680.

831   21.   Pearce EJ, C MK, Sun J, J JT, McKee AS, Cervi L: **Th2 response polarization during**
832   **infection with the helminth parasite Schistosoma mansoni.** *Immunol Rev* 2004,
833   **201:**117-126.

834   22.   Everts B, Hussaarts L, Driessen NN, Meevissen MH, Schramm G, van der Ham AJ, van
835   der Hoeven B, Scholzen T, Burgdorf S, Mohrs M, et al: **Schistosome-derived omega-1**
836   **drives Th2 polarization by suppressing protein synthesis following internalization**
837   **by the mannose receptor.** *J Exp Med* 2012, **209:**1753-1767, S1751.

838   23.   Dunne DW, Jones FM, Doenhoff MJ: **The purification, characterization, serological**
839   **activity and hepatotoxic properties of two cationic glycoproteins (alpha 1 and omega**
840   **1) from Schistosoma mansoni eggs.** *Parasitology* 1991, **103 Pt 2:**225-236.

24. Curwen RS, Ashton PD, Johnston DA, Wilson RA: **The Schistosoma mansoni soluble**
proteome: a comparison across four life-cycle stages. *Mol Biochem Parasitol* 2004,
138:57-66.

25. Ashton PD, Harrop R, Shah B, Wilson RA: **The schistosome egg: development and**
secretions. *Parasitology* 2001, **122:**329-338.

26. Cass CL, Johnson JR, Califf LL, Xu T, Hernandez HJ, Stadecker MJ, Yates JR, 3rd,
Williams DL: **Proteomic analysis of Schistosoma mansoni egg secretions.** *Mol*
Biochem Parasitol 2007, **155:**84-93.

27. Mathieson W, Wilson RA: **A comparative proteomic study of the undeveloped and**
developed Schistosoma mansoni egg and its contents: the miracidium, hatch fluid
and secretions. *Int J Parasitol* 2010, **40:**617-628.

28. Wilbers RH, Westerhof LB, van Noort K, Obieglo K, Driessen NN, Everts B, Gringhuis
SI, Schramm G, Goverse A, Smant G, et al: **Production and glyco-engineering of**
immunomodulatory helminth glycoproteins in plants. *Sci Rep* 2017, **7:**45910.

29. Fitzsimmons CM, Schramm G, Jones FM, Chalmers IW, Hoffmann KF, Grevelding CG,
Wuhrer M, Hokke CH, Haas H, Doenhoff MJ, Dunne DW: **Molecular characterization**
of omega-1: a hepatotoxic ribonuclease from Schistosoma mansoni eggs. *Mol*
Biochem Parasitol 2005, **144:**123-127.

30. Ferguson BJ, Newland SA, Gibbs SE, Tourlomousis P, Fernandes dos Santos P, Patel
MN, Hall SW, Walczak H, Schramm G, Haas H, et al: **The Schistosoma mansoni T2**
ribonuclease omega-1 modulates inflammasome-dependent IL-1beta secretion in
macrophages. *Int J Parasitol* 2015, **45:**809-813.

31. Wynn TA, Thompson RW, Cheever AW, Mentink-Kane MM: **Immunopathogenesis of**
schistosomiasis. *Immunol Rev* 2004, **201:**156-167.

32. Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA, Charpentier E: **A programmable**
dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. *Science* 2012,
337:816-821.

33. Hsu PD, Lander ES, Zhang F: **Development and applications of CRISPR-Cas9 for**
genome engineering. *Cell* 2014, **157:**1262-1278.

34. Murare HM, Dunne DW, Bain J, Doenhoff MJ: **Schistosoma mansoni: control of**
hepatotoxicity and egg excretion by immune serum in infected immunosuppressed
mice is schistosome species-specific, but not S. mansoni strain-specific. *Exp Parasitol*
1992, **75:**329-339.

35. M LZZYB: **A web portal for gene expression across all life stages of Schistosoma**
mansoni. *bioRxiv* 2018.

36. Lee AH, Symington LS, Fidock DA: **DNA repair mechanisms and their biological**
roles in the malaria parasite Plasmodium falciparum. *Microbiol Mol Biol Rev* 2014,
78:469-486.

37. Deriano L, Roth DB: **Modernizing the nonhomologous end-joining repertoire:**
alternative and classical NHEJ share the stage. *Annu Rev Genet* 2013, **47:**433-455.

38. Consortium IHG: **Comparative genomics of the major parasitic worms.** *bioRxiv* 2017,
https://http://www.biorxiv.org/content/early/2017/12/20/236539

39. Lok JB, Shao H, Massey HC, Li X: **Transgenesis in Strongyloides and related**
parasitic nematodes: historical perspectives, current functional genomic
applications and progress towards gene disruption and editing. *Parasitology* 2017,
144:327-342.

40. Gang SS, Castelletto ML, Bryant AS, Yang E, Mancuso N, Lopez JB, Pellegrini M,
Hallem EA: **Targeted mutagenesis in a human-parasitic nematode.** *PLoS Pathog*
2017, **13:**e1006675.

41. Chen F, Pruett-Miller SM, Davis GD: **Gene editing using ssODNs with engineered**
endonucleases. *Methods Mol Biol* 2015, **1239:**251-265.

42. Duvoisin R, Ayuk MA, Rinaldi G, Suttiprapa S, Mann VH, Lee CM, Harris N, Brindley
PJ: **Human U6 promoter drives stronger shRNA activity than its schistosome**
orthologue in Schistosoma mansoni and human fibrosarcoma cells. *Transgenic Res*
2012, **21:**511-521.

43. Suttiprapa S, Rinaldi G, Tsai IJ, Mann VH, Dubrovsky L, Yan HB, Holroyd N, Huckvale
T, Durrant C, Protasio AV, et al: **HIV-1 Integrates Widely throughout the Genome of**
the Human Blood Fluke Schistosoma mansoni. *PLoS Pathog* 2016, **12:**e1005931.

44. Shah AN, Davey CF, Whitebirch AC, Miller AC, Moens CB: **Rapid reverse genetic**
screening using CRISPR in zebrafish. *Nat Methods* 2015, **12:**535-540.

45. Yu C, Zhang Y, Yao S, Wei Y: **A PCR based protocol for detecting indel mutations**
induced by TALENs and CRISPR/Cas9 in zebrafish. *PLoS One* 2014, **9:**e98282.

46. Pinello L, Canver MC, Hoban MD, Orkin SH, Kohn DB, Bauer DE, Yuan GC:
Analyzing CRISPR genome-editing experiments with CRISPResso. *Nat Biotechnol*
2016, **34:**695-697.

47. Suttiprapa S, Rinaldi G, Brindley PJ: **Prototypic chromatin insulator cHS4 protects**
retroviral transgene from silencing in Schistosoma mansoni. *Transgenic Res* 2012,
21:555-566.

48. Ke XD, Shen S, Song LJ, Yu CX, Kikuchi M, Hirayama K, Gao H, Wang J, Yin X, Yao
Y, et al: **Characterization of Schistosoma japonicum CP1412 protein as a novel**
member of the ribonuclease T2 molecule family with immune regulatory function.
Parasit Vectors 2017, **10:**89.

49. Zaccone P, Burton OT, Gibbs SE, Miller N, Jones FM, Schramm G, Haas H, Doenhoff
MJ, Dunne DW, Cooke A: **The S. mansoni glycoprotein omega-1 induces Foxp3**
expression in NOD mouse CD4(+) T cells. *Eur J Immunol* 2011, **41:**2709-2718.

50. Ritter M, Gross O, Kays S, Ruland J, Nimmerjahn F, Saijo S, Tschopp J, Layland LE,
Prazeres da Costa C: **Schistosoma mansoni triggers Dectin-2, which activates the**
Nlrp3 inflammasome and alters adaptive immune responses. *Proc Natl Acad Sci U S*
A 2010, **107:**20459-20464.

51. Qin Z: **The use of THP-1 cells as a model for mimicking the function and regulation**
of monocytes and macrophages in the vasculature. *Atherosclerosis* 2012, **221:**2-11.

52. Fuentes L, Hernandez M, Fernandez-Aviles FJ, Crespo MS, Nieto ML: **Cooperation**
between secretory phospholipase A2 and TNF-receptor superfamily signaling:
implications for the inflammatory response in atherogenesis. *Circ Res* 2002, **91:**681-
688.

53. Doenhoff MJ, Hassounah O, Murare H, Bain J, Lucas S: **The schistosome egg**
granuloma: immunopathology in the cause of host protection or parasite survival?
Trans R Soc Trop Med Hyg 1986, **80:**503-514.

54. Boros DL, Warren KS: **Delayed hypersensitivity-type granuloma formation and**
dermal reaction induced and elicited by a soluble factor isolated from Schistosoma
mansoni eggs. *J Exp Med* 1970, **132:**488-507.

55. Eltoum IA, Wynn TA, Poindexter RW, Finkelman FD, Lewis FA, Sher A, Cheever AW:
Suppressive effect of interleukin-4 neutralization differs for granulomas around
Schistosoma mansoni eggs injected into mice compared with those around eggs laid
in infected mice. *Infect Immun* 1995, **63:**2532-2536.

56. Wynn TA, Eltoum I, Cheever AW, Lewis FA, Gause WC, Sher A: **Analysis of cytokine**
mRNA expression during primary granuloma formation induced by eggs of
Schistosoma mansoni. *J Immunol* 1993, **151:**1430-1440.

57. Lieber MR: **The mechanism of double-strand DNA break repair by the**
nonhomologous DNA end-joining pathway. *Annu Rev Biochem* 2010, **79:**181-211.

58. Paquet D, Kwart D, Chen A, Sproul A, Jacob S, Teo S, Olsen KM, Gregg A, Noggle S,
Tessier-Lavigne M: **Efficient introduction of specific homozygous and heterozygous**
mutations using CRISPR/Cas9. *Nature* 2016, **533:**125-129.

59.   Zhang WW, Matlashewski G: **CRISPR-Cas9-Mediated Genome Editing in**
Leishmania donovani. *MBio* 2015, **6:**e00861.

60.   Yoshimi K, Kunihiro Y, Kaneko T, Nagahora H, Voigt B, Mashimo T: **ssODN-mediated**
knock-in with CRISPR-Cas for large genomic regions in zygotes. *Nature*
communications 2016, **7:**10431.

61.   Kosicki M, Rajan SS, Lorenzetti FC, Wandall HH, Narimatsu Y, Metzakopian E, Bennett
EP: **Dynamics of Indel Profiles Induced by Various CRISPR/Cas9 Delivery**
Methods. *Prog Mol Biol Transl Sci* 2017, **152:**49-67.

62.   Holmgaard A, Askou AL, Benckendorff JNE, Thomsen EA, Cai Y, Bek T, Mikkelsen
JG, Corydon TJ: **In Vivo Knockout of the Vegfa Gene by Lentiviral Delivery of**
CRISPR/Cas9 in Mouse Retinal Pigment Epithelium Cells. *Mol Ther Nucleic Acids*
2017, **9:**89-99.

63.   Yu Z, Chen Q, Chen W, Zhang X, Mei F, Zhang P, Zhao M, Wang X, Shi N, Jackson S,
Hong Y: **Multigene editing via CRISPR/Cas9 guided by a single-sgRNA seed in**
Arabidopsis. *J Integr Plant Biol* 2018, **60:**376-381.

64.   Luo JJ, Bian WP, Liu Y, Huang HY, Yin Q, Yang XJ, Pei DS: **CRISPR/Cas9-based**
genome engineering of zebrafish using a seamless integration strategy. *FASEB J*
2018**:**fj201800077RR.

65.   Shalem O, Sanjana NE, Zhang F: **High-throughput functional genomics using**
CRISPR-Cas9. *Nat Rev Genet* 2015, **16:**299-311.

66.   Jurberg AD, Goncalves T, Costa TA, de Mattos AC, Pascarelli BM, de Manso PP,
Ribeiro-Alves M, Pelajo-Machado M, Peralta JM, Coelho PM, Lenzi HL: **The**
embryonic development of Schistosoma mansoni eggs: proposal for a new staging
system. *Dev Genes Evol* 2009, **219:**219-234.

67.   Neill PJ, Smith JH, Doughty BL, Kemp M: **The ultrastructure of the Schistosoma**
mansoni egg. *Am J Trop Med Hyg* 1988, **39:**52-65.

68.   Mann VH, Suttiprapa S, Rinaldi G, Brindley PJ: **Establishing transgenic schistosomes.**
PLoS Negl Trop Dis 2011, **5:**e1230.

69.   Heyer WD, Ehmsen KT, Liu J: **Regulation of homologous recombination in**
eukaryotes. *Annu Rev Genet* 2010, **44:**113-139.

70.   Lu Z, ; Zhang, Y.; Berriman, M.: **A web portal for gene expression across all life**
stages of Schistosoma mansoni. *bioRxiv* 2018.

71.   Schramm G, Hamilton JV, Balog CI, Wuhrer M, Gronow A, Beckmann S, Wippersteg V,
Grevelding CG, Goldmann T, Weber E, et al: **Molecular characterisation of kappa-5, a**

major antigenic glycoprotein from Schistosoma mansoni eggs. *Mol Biochem Parasitol*
2009, **166:**4-14.

72. Kaisar MMM, Ritter M, Del Fresno C, Jonasdottir HS, van der Ham AJ, Pelgrom LR,
Schramm G, Layland LE, Sancho D, Prazeres da Costa C, et al: **Dectin-1/2-induced**
autocrine PGE2 signaling licenses dendritic cells to prime Th2 responses. *PLoS Biol*
2018, **16:**e2005504.

73. Mann VH, Suttiprapa S, Skinner DE, Brindley PJ, Rinaldi G: **Pseudotyped murine**
leukemia virus for schistosome transgenesis: approaches, methods and perspectives.
Transgenic Res 2014, **23:**539-556.

74. Dalton JP, Day SR, Drew AC, Brindley PJ: **A method for the isolation of schistosome**
eggs and miracidia free of contaminating host tissues. *Parasitology* 1997, **115 (Pt**
1):29-32.

75. Mann VH, Morales ME, Rinaldi G, Brindley PJ: **Culture for genetic manipulation of**
developmental stages of Schistosoma mansoni. *Parasitology* 2010, **137:**451-462.

76. Cardoso LS, Araujo MI, Goes AM, Pacifico LG, Oliveira RR, Oliveira SC: **Polymyxin B**
as inhibitor of LPS contamination of Schistosoma mansoni recombinant proteins in
human cytokine analysis. *Microb Cell Fact* 2007, **6:**1.

77. Bradford MM: **A rapid and sensitive method for the quantitation of microgram**
quantities of protein utilizing the principle of protein-dye binding. *Anal Biochem*
1976, **72:**248-254.

78. Oliveros JC, Franch M, Tabas-Madrid D, San-Leon D, Montoliu L, Cubas P, Pazos F:
Breaking-Cas-interactive design of guide RNAs for CRISPR-Cas experiments for
ENSEMBL genomes. *Nucleic Acids Res* 2016, **44:**W267-271.

79. Minskaia E, Nicholson J, Ryan MD: **Optimisation of the foot-and-mouth disease virus**
2A co-expression system for biomedical applications. *BMC Biotechnol* 2013, **13:**67.

80. Lok JB, Shao H, Massey HC, Li X: **Transgenesis in Strongyloides and related**
parasitic nematodes: historical perspectives, current functional genomic
applications and progress towards gene disruption and editing. *Parasitology* 2016**:**1-
16.

81. Marozsan AJ, Fraundorf E, Abraha A, Baird H, Moore D, Troyer R, Nankja I, Arts EJ:
Relationships between infectious titer, capsid protein levels, and reverse
transcriptase activities of diverse human immunodeficiency virus type 1 isolates. *J*
Virol 2004, **78:**11130-11141.

82. Martin M: **Cutadapt removes adapter sequences from high-throughput sequencing**
reads. *EMBnetjournal North America* 2011,
http://journal.embnet.org/index.php/embnetjournal/article/view/200/458.

83. Canver MC, Haeussler M, Bauer DE, Orkin SH, Sanjana NE, Shalem O, Yuan GC,
Zhang F, Concordet JP, Pinello L: **Integrated design, execution, and analysis of**
arrayed and pooled CRISPR genome-editing experiments. *Nat Protoc* 2018, **13:**946-
986.

84. Pearson WR, Lipman DJ: **Improved tools for biological sequence comparison.** *Proc*
Natl Acad Sci U S A 1988, **85:**2444-2448.

85. Ginzinger DG: **Gene quantification using real-time quantitative PCR: an emerging**
technology hits the mainstream. *Exp Hematol* 2002, **30:**503-512.

86. Livak KJ, Schmittgen TD: **Analysis of relative gene expression data using real-time**
quantitative PCR and the 2(-Delta Delta C(T)) Method. *Methods* 2001, **25:**402-408.

87. Chomczynski P: **A reagent for the single-step simultaneous isolation of RNA, DNA**
and proteins from cell and tissue samples. *Biotechniques* 1993, **15:**532-534, 536-537.

88. Genin M, Clement F, Fattaccioli A, Raes M, Michiels C: **M1 and M2 macrophages**
derived from THP-1 cells differentially modulate the response of cancer cells to
etoposide. *BMC Cancer* 2015, **15:**577.

89. Schmid MC, Varner JA: **Myeloid cells in the tumor microenvironment: modulation of**
tumor angiogenesis and tumor inflammation. *J Oncol* 2010, **2010:**201026.

90. Cheever AW, Finkelman FD, Caspar P, Heiny S, Macedonia JG, Sher A: **Treatment**
with anti-IL-2 antibodies reduces hepatic pathology and eosinophilia in Schistosoma
mansoni-infected mice while selectively inhibiting T cell IL-5 production. *J Immunol*
1992, **148:**3244-3248.

91. Crooks GE, Hon G, Chandonia JM, Brenner SE: **WebLogo: a sequence logo generator.**
Genome Res 2004, **14:**1188-1190.

92. Gieseck RL, 3rd, Wilson MS, Wynn TA: **Type 2 immunity in tissue repair and**
fibrosis. *Nat Rev Immunol* 2018, **18:**62-76.

93. Wynn TA: **Type 2 cytokines: mechanisms and therapeutic strategies.** *Nat Rev*
Immunol 2015, **15:**271-282.

1041

1042

Figure 3

Figure 4